Aktis Oncology Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$175M
- Investors
-
23
Aktis Oncology General Information
Description
Developer of a targeted radiopharmaceutical designed to treat a broad range of solid tumor cancers. The company's radiopharmaceuticals generate cells-targeting agents with ideal properties for alpha radiotherapy, that are designed for high tumor penetration and long residence time, enabling clinicians to maximize tumor elimination while minimizing side effects of treatment.
Contact Information
Website
www.aktisoncology.comCorporate Office
- 17 Drydock Avenue
- Suite 17-401
- Boston, MA 02210
- United States
Corporate Office
- 17 Drydock Avenue
- Suite 17-401
- Boston, MA 02210
- United States
Aktis Oncology Timeline
Aktis Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series B) | 20-Sep-2024 | $175M | Completed | Pre-Clinical Trials | ||
| 4. Secondary Transaction - Private | 13-Feb-2024 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 17-Aug-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 18-Mar-2021 | $72M | $77M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Mar-2021 | $5M | $5M | Completed | Pre-Clinical Trials |
Aktis Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Partner Pref | ||||||||
| Seed | 5,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 5.43% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aktis Oncology Comparisons
Industry
Financing
Details
Aktis Oncology Competitors (77)
One of Aktis Oncology’s 77 competitors is Meditope Biosciences, a Venture Capital-Backed company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Laryat Therapeutics | Venture Capital-Backed | San Diego, CA | ||||
| Amal Therapeutics | Formerly VC-backed | Geneva, Switzerland | ||||
| Tizona Therapeutics | Venture Capital-Backed | San Francisco, CA |
Aktis Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aktis Oncology Patents
Aktis Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023379454-A1 | Decreased retention of miniproteins in kidney | Pending | 14-Nov-2022 | ||
| EP-4551255-A2 | Nectin-4 miniprotein conjugates | Pending | 07-Jul-2022 |
Aktis Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aktis Oncology Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avidity Partners | Asset Manager | Minority | ||
| Baker Brothers Investments | Hedge Fund | Minority | ||
| Bristol-Myers Squibb Foundation | Limited Partner | Minority | ||
| Eli Lilly | Corporation | Minority | ||
| Janus Henderson Investors | Asset Manager | Minority |
Aktis Oncology FAQs
-
When was Aktis Oncology founded?
Aktis Oncology was founded in 2021.
-
Where is Aktis Oncology headquartered?
Aktis Oncology is headquartered in Boston, MA.
-
What is the size of Aktis Oncology?
Aktis Oncology has 46 total employees.
-
What industry is Aktis Oncology in?
Aktis Oncology’s primary industry is Drug Discovery.
-
Is Aktis Oncology a private or public company?
Aktis Oncology is a Private company.
-
What is Aktis Oncology’s current revenue?
The current revenue for Aktis Oncology is .
-
How much funding has Aktis Oncology raised over time?
Aktis Oncology has raised $336M.
-
Who are Aktis Oncology’s investors?
Avidity Partners, Baker Brothers Investments, Bristol-Myers Squibb Foundation, Eli Lilly, and Janus Henderson Investors are 5 of 23 investors who have invested in Aktis Oncology.
-
Who are Aktis Oncology’s competitors?
Meditope Biosciences, Aro Biotherapeutics, Laryat Therapeutics, Amal Therapeutics, and Tizona Therapeutics are some of the 77 competitors of Aktis Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
